FDA and CDC Clear Reformulated mRNA COVID-19 Vaccines for Fall 2024 Use

FDA Authorizes Updated 2024-2025 COVID-19 Vaccines Targeting KP.2 Lineage

The FDA authorized updated COVID-19 vaccines on August 22, 2024 for use in the upcoming season. The mRNA vaccines from Moderna and Pfizer-BioNTech plus Novavax's adjuvanted protein vaccine all target the KP.2 lineage of the JN.1 variant of SARS-CoV-2. The strain was picked after advisory review of surveillance data to improve antigenic match with dominant circulating viruses. The CDC issued follow-on guidance days later that spelled out dosing for individuals six months and older.

The FDA based its decision on advice from its Vaccines and Related Biological Products Advisory Committee. That committee examined recent variant trends and backed the shift to KP.2. Manufacturers will rely on the same platforms used in previous versions. Regulators accepted bridging studies instead of new large clinical efficacy trials for this exact formulation.

FDA strain selection details

The FDA announcement states that KP.2 was selected to better match currently circulating SARS-CoV-2 variants. This lineage is part of the JN.1 family and had risen in prominence by mid-2024. The agency cleared the Moderna and Pfizer-BioNTech mRNA vaccines for people six months and older. It authorized Novavax's version for adults 12 and older, with age-specific dosing instructions in the labels.

Authorization rested on manufacturing consistency data, immunogenicity results from earlier versions, and established safety records. The FDA did not require fresh clinical endpoint studies for the KP.2 antigen itself.

CDC recommendations

The Advisory Committee on Immunization Practices issued its guidance on August 27, 2024 in the CDC's Morbidity and Mortality Weekly Report. The group recommended that everyone six months and older receive an updated vaccine. Most people who were previously vaccinated need only a single dose this season.

The report also addresses dosing intervals after prior vaccination. It notes that some immunocompromised persons may need additional doses based on clinical judgment. These details put the FDA authorizations into practice for the 2024-2025 respiratory virus season.

Global alignment

The World Health Organization issued its statement on antigen composition on April 26, 2024. Its technical advisory group supported vaccines built on the JN.1 lineage. KP.2 descends directly from JN.1, so the FDA selection fits that international recommendation.

SARS-CoV-2 continues to change. Periodic vaccine updates seek to keep pace with dominant strains.

What this means

This sequence of decisions sets the exact composition for vaccines that will ship during the fall and winter. The KP.2 target replaces the XBB.1.5 or earlier JN.1 components used in 2023-2024 products. Distribution can begin with these strain-matched doses. Real-world data on how well they perform will come from observational studies that start after rollout.

Key takeaways

• The FDA authorized Moderna and Pfizer-BioNTech mRNA vaccines plus Novavax's adjuvanted vaccine targeting the KP.2 lineage on August 22, 2024. [1]
• KP.2 was chosen following VRBPAC review of variant surveillance to align with strains then in circulation within the JN.1 family. [1]
• CDC guidance released August 27 recommends the 2024-2025 formula for all persons aged 6 months and older, with one dose for most previously vaccinated individuals. [2]
• The choice aligns with the WHO technical statement from April 2024 that endorsed JN.1 lineage antigens. [3]
• The authorization drew on manufacturing data, immunogenicity bridging, and safety information from prior versions rather than new KP.2-specific efficacy trials. [1][2]

Limitations

Clinical effectiveness data for the precise KP.2 formulation will be generated post-authorization through observational studies. Authorization relies on manufacturing consistency, immunogenicity bridging, and safety from prior versions. Continued variant evolution may reduce match over time. Product-specific pediatric dosing schedules and contraindications differ and are detailed in each manufacturer's labeling.

FAQ

Which manufacturers received FDA authorization for the 2024-2025 KP.2-targeted COVID-19 vaccines?
Moderna and Pfizer-BioNTech for mRNA vaccines plus Novavax for its adjuvanted protein-based shot. [1]

What evidence and advisory processes informed the FDA's selection of the KP.2 lineage?
VRBPAC reviewed variant surveillance data and recommended KP.2. The choice also aligns with WHO technical advice on the JN.1 lineage. [1][3]

How do CDC recommendations align with the FDA authorization for use of these updated vaccines?
ACIP endorsed use of the newly authorized formulations in all persons 6 months and older, with dosing details that match the FDA approvals. [2]

Sources / References

[1] FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-takes-action-updated-mrna-covid-19-vaccines-better-protect-against-currently-circulating

[2] Use of Updated COVID-19 Vaccines 2024-2025 Formula Among Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices, United States, 2024. Centers for Disease Control and Prevention. https://www.cdc.gov/mmwr/volumes/73/wr/mm7332a3.htm

[3] Statement on the antigen composition of COVID-19 vaccines. World Health Organization. https://www.who.int/news/item/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines